



June 22, 2026

To whom it may concern:

Company Name: TOHO HOLDINGS CO.,LTD.
Corporate Representative: Hiromi Edahiro, Representative Director,
President and CEO
(Prime Market of Tokyo Stock
Exchange Securities Code: 8129)
Contact: Makoto Kawamura, Executive Corporate
Officer and General Manager, Corporate
Strategy Division
(TEL: 81-3-6838-2803)

Announcement of Investment in Rege Nephro Co., Ltd.

TOHO HOLDINGS CO.,LTD. (Headquarters: Tokyo; Representative Director, President and CEO: Hiromi Edahiro; hereinafter “TOHO HOLDINGS”) is pleased to announce that it has invested in Rege Nephro Co., Ltd. (Headquarters: Kyoto; CEO: Akifumi Morinaka; hereinafter, “Rege Nephro”), a clinical-stage biotechnology startup focused on iPS cell-based kidney regenerative medicine and drug discovery, as described below.

1. Purpose of investment

TOHO HOLDINGS is a corporate group active in the medical, nursing and healthcare fields, engaged in pharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer support systems under the Group slogan “Total Commitment to Good Health”. TOHO HOLDINGS also proactively promotes initiatives for regional medical collaboration, nursing and home care.

Rege Nephro is a clinical-stage drug discovery startup that leverages cutting-edge technology based on the research seeds of Professor Kenji Osafune at Kyoto University’s Center for iPS Cell Research and Application (CiRA). Grounded in iPS cell technology, the company’s corporate philosophy is to revolutionize treatment options for intractable diseases, with a primary focus on kidney disorders, and to create a future where people worldwide are free from the burden of illness.

Rege Nephro's lead development pipeline candidate, "RN-014" (a novel therapeutic drug candidate for autosomal dominant polycystic kidney disease (ADPKD)), has reached LPLV (Last Patient Last Visit) in its Phase 2a clinical trial, marking a pivotal milestone toward practical commercialization.

Through this investment, TOHO HOLDINGS will support Rege Nephro’s research and development while deepening our knowledge of regenerative medical products, which are expected to grow in the future. Furthermore, we will fully cooperate in the distribution of their products and strive to ensure that patients suffering from intractable diseases can receive innovative treatments with peace of mind.

2. Overview of Rege Nephro

- (1) Company name: Rege Nephro Co., Ltd.
- (2) Location: Med-Pharm Collaboration bldg. Kyoto University 46-29 Yoshidashimoadachi-cho, Sakyo-ku, Kyoto 606-8501 JAPAN
- (3) Representative: Akifumi Morinaka, CEO
- (4) Established: September 20, 2019
- (5) Business content: R&D, production, and sales of therapeutic drugs for renal diseases
- (6) Capital: JPY 2,276,093,400 (Including capital reserve)

3. Forward looking outlook

While we expect that this transaction will have only a negligible impact on consolidated earnings of TOHO HOLDINGS, we believe that it will contribute to increase the Group’s corporate value over the medium to long term. The Company will disclose any impact promptly if it becomes necessary to do so in the future.

Note: This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.